Welcome to our dedicated page for Savara SEC filings (Ticker: SVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Savara Inc. (SVRA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases, and its filings offer detailed insight into the development and financing of its lead program, MOLBREEVI, for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
Through this page, readers can review current and historical reports such as Forms 8-K, which describe material events including public offerings of common stock and pre-funded warrants, royalty funding agreements tied to potential future U.S. net sales of MOLBREEVI, and updates to corporate presentations. Filings also confirm that Savara’s common stock trades on The Nasdaq Global Select Market under the symbol SVRA and describe the company’s status as a clinical stage biopharmaceutical company focused on rare respiratory diseases.
Key documents for investors include periodic reports like annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain information on research and development expenses, general and administrative costs, and other financial data related to the MOLBREEVI program and corporate operations. Current reports on Form 8-K highlight transactions such as underwritten public offerings, the entry into material definitive agreements, and royalty funding arrangements.
Stock Titan enhances these filings with AI-powered summaries that help explain the significance of complex disclosures, including capital-raising transactions, royalty structures, and covenants described in agreements. Users can quickly understand how specific filings relate to Savara’s rare respiratory disease focus, its Phase 3 development of MOLBREEVI, and its preparation for potential commercialization, while still having direct access to the full text of each SEC document.
Venrock-affiliated investment entities report beneficial ownership of 20,881,288 Savara Inc. shares, representing 9.99% of the common stock as of December 31, 2025. This stake comes from common shares and pre-funded warrants held across several Venrock Healthcare Capital Partners funds.
The pre-funded warrants include a 9.99% Beneficial Ownership Blocker, which prevents additional exercises that would push the group’s ownership above that level. The reporting group certifies that the securities are not held for the purpose of changing or influencing control of Savara.
Savara Inc director Joseph S. McCracken exercised stock options on
Savara Inc. received an updated ownership report from TCG Crossover entities and Chen Yu. They report beneficial ownership of 12,362,205 shares of Savara common stock, representing 6.1% of the class, based on 203,467,845 shares outstanding as of November 12, 2025.
The shares are held of record by TCG Crossover Fund I, L.P., with TCG Crossover GP I, LLC as its general partner and Chen Yu as sole managing member, giving them shared voting and dispositive power. The filers state the holdings are not for the purpose of changing or influencing control of Savara.
Savara Inc. (SVRA) received an amended Schedule 13G filing from a group of Frazier Life Sciences investment entities reporting beneficial ownership of less than 5% of its common stock.
Frazier Life Sciences Public Fund, L.P. directly holds 8,343,048 shares, representing 4.1% of the class based on 203,467,845 shares outstanding as of November 12, 2025. Frazier Life Sciences X, L.P. directly holds 279,365 shares (0.1%), and Frazier Life Sciences XI, L.P. directly holds 1,239,888 shares (0.6%).
The reporting persons certify the securities were not acquired or held to change or influence control of Savara and disclaim being part of a control group, other than for limited nomination activities cited in the certification language.
Savara Inc. (SVRA) received an amended Schedule 13G from Nantahala Capital Management and its principals, Wilmot B. Harkey and Daniel Mack, reporting their beneficial ownership in the company’s common stock. As of December 31, 2025, they may be deemed to beneficially own 7,344,783 shares, representing 3.61% of Savara’s outstanding common stock.
The filing shows they have no sole voting or dispositive power, but share voting and dispositive power over all reported shares through funds and accounts managed by Nantahala. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Savara.
Savara Inc. received an updated Schedule 13G/A (Amendment No. 10) from a group of Farallon-managed investment funds reporting their beneficial ownership in the company’s common stock. The Farallon funds collectively hold 15,000,000 Common Stock Purchase Warrants, each currently exercisable to buy one Savara share.
Because the warrants contain a 9.99% Beneficial Ownership Limitation, Farallon reports beneficial ownership of 6.9% of Savara’s common stock, based on assuming all 15,000,000 warrants are exercisable within 60 days. The amendment also updates the listed individual reporting persons, adding Avner A. Husen and removing Richard B. Fried, Rajiv A. Patel, and William Seybold as of year-end 2025.
Savara Inc. entered into a First Amendment to its Loan and Security Agreement with Hercules Capital and other lenders. As amended, the agreement allows the company to borrow up to an aggregate of $105 million in term loans. The amendment resets the timing and conditions for Savara to draw up to $75 million of additional term loans, which become available only if the FDA approves its MOLBREEVI product candidate for treating aPAP. It also pushes back the initial dates for certain cash and revenue financial covenants to April 1, 2027 and September 30, 2027 if Savara’s market capitalization falls below specified thresholds, and grants lenders a first‑priority security interest in the company’s intellectual property, which can revert to a negative pledge if a related purchase agreement is terminated and unrestricted cash remains at or above $50 million.
BlackRock, Inc. has disclosed a significant ownership stake in Savara Inc. common stock on a Schedule 13G. BlackRock reports beneficial ownership of 10,957,322 shares of Savara common stock, representing 5.4% of the outstanding class as of the event date 12/31/2025. BlackRock has sole voting power over 10,820,963 shares and sole dispositive power over 10,957,322 shares, with no shared voting or dispositive power.
The filing states that these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Savara. Various underlying clients and investors have the right to receive dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares.
Savara Inc. has furnished an updated corporate presentation for investors. The presentation is available on the company’s Investor Relations website and has also been provided as Exhibit 99.1 to a current report. Savara states it has no duty to update or revise the presentation, although it may choose to do so through its website, future SEC reports, press releases, or other public disclosures. The information in this investor presentation is expressly treated as furnished rather than filed under securities laws and is not automatically incorporated into other SEC filings unless specifically referenced.
Savara Inc's Chief Financial Officer, David Lowrance, reported two transactions in the company’s common stock. On December 14, 2025, 62,960 shares were disposed of at $6.92 per share, representing shares withheld by Savara to cover tax liabilities from the vesting of previously awarded restricted stock units, leaving him with 318,045 shares owned directly.
On December 16, 2025, he reported a bona fide gift of 32,000 shares to The McCallie School at a reported price of $0.00 per share, after which he directly owned 286,045 shares of Savara common stock. He does not have voting or investment power over the shares held by The McCallie School.